Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 01, 2019

SELL
$2.5 - $3.73 $481,912 - $719,013
-192,765 Closed
0 $0
Q2 2019

Aug 07, 2019

BUY
$2.91 - $9.15 $560,946 - $1.76 Million
192,765 New
192,765 $730,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.39B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Premier Asset Management LLC Portfolio

Follow Premier Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Premier Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Premier Asset Management LLC with notifications on news.